Related Experiment Video
Updated: Sep 30, 2025

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
Published on: September 1, 2023
Effect of Chronic Valproic Acid Use on Anterior Cerebral Blood Flow of Children with Idiopathic Generalized Epilepsy
Hamit Ozyurek1, Ilkay Bayrak2, Ozlem Yayici Koken3
1the Department of Pediatrics, Pediatric Neurology Division, Ondokuz Mayis University;Pediatric Neurology Unit, Ministry of Health Ankara City Hospital.
Insights
Valproic acid (VPA) treatment for epilepsy in children did not alter cerebral blood flow. However, further research is needed to determine if VPA impacts neurocognition in these patients.
Area of Science:
- Neurology
- Pediatrics
- Medical Imaging
Background:
- Antiepileptic drugs are associated with neurocognitive deficits.
- Cerebral blood flow changes are hypothesized to contribute to these deficits.
- Valproic acid (VPA) is a common antiepileptic drug used for idiopathic generalized epilepsy (IGE).
Purpose of the Study:
- To investigate the effect of VPA on cerebral blood flow in children with IGE.
- To determine if VPA treatment alters key hemodynamic parameters in pediatric patients.
Main Methods:
- Doppler and spectral measurements were performed on 33 children with IGE on VPA and 34 age-matched controls.
- Measurements included common carotid artery (CCA), internal carotid artery (ICA), external carotid artery (ECA), anterior cerebral artery (ACA), and middle cerebral artery (MCA).
- Calculated parameters included maximum velocity (VM), end-diastolic velocity (EDV), resistive index (RI), pulsatility index (PI), and flow rate (FR).
Main Results:
- No statistically significant differences were observed in VM, EDV, RI, PI, or FR between the VPA group and controls.
- These hemodynamic parameters were measured in the bilateral ICA, ACA, and MCA.
- The study included children with a mean age of approximately 9.5 years, with a follow-up of over 17 months.
Conclusions:
- Therapeutic doses of VPA did not demonstrate an effect on anterior cerebral blood flow in children with IGE.
- Despite no observed changes in cerebral blood flow, it remains challenging to definitively rule out neurocognitive deterioration in patients receiving VPA.
- Further investigation is warranted to fully understand the relationship between VPA, cerebral blood flow, and neurocognitive outcomes in pediatric epilepsy patients.
Objective:
Cerebral blood flow has been blamed as a factor in the negative effect of antiepileptic drugs on neurocognition. This study aimed to investigate whether valproic acid (VPA), used for the treatment of idiopathic generalized epilepsy (IGE), causes a change in cerebral blood flow in children.
Methods:
Included in this study were 33 children who were receiving VPA for IGE and 34 age-matched controls. Doppler and spectral measurements in common carotid artery (CCA), left and right internal CA (ICA) and external CA (ECA), anterior cerebral artery (ACA) and middle cerebral artery (MCA) were performed and the maximum velocity (VM), end-diastolic velocity (EDV), resistive index (RI), pulsatility index (PI) and flow rate (FR) were calculated.
Results:
The mean age of drug and control groups were 9.33 plus or minus 2.11, and 9.74 plus or minus 2 years, respectively. Follow-up of patients was 17.7 plus or minus 3.2 months. The period of VPA treatment was 17.4 plus or minus 3.4 months. No statistically significant differences were found between control and VPA group for the VM, EDV, RI, PI, and FR values obtained from the bilateral ICA, ACA, and MCA.
Conclusions:
The results showed that VPA in therapeutic doses did not affect anterior cerebral blood flow. However according to result, it is still difficult to conclude that neurocognitive deterioration is not observed in patients receiving VPA.
More Related Videos
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
06:24Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
Published on: July 8, 2025
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...